Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site for transcribing mRNA; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.

Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human lipocortin-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human lipocortin-like polypeptide. In appropriate hosts these DNA sequences permit the production of human lipocortin-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.

Abstract: A mixed composition polyhedral inclusion body (PIB) is provided which contains a mixture of nucleocapsids of at least two genetically distinct baculoviruses. At least one of the baculoviruses is genetically engineered to contain at least one heterologous gene. Followed ingestion of the mixed composition PIB by an insect host, a mixed viral infection ensues in the insect permitting the production therein of additional copies of the mixed composition PIB and the production of a heterologous protein encoded by the heterologous gene present in at least one of the baculoviruses.

Abstract: The present invention provides DNA compounds that encode deacetoxycephalosporin C synthetase (DAOCS) activity. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Streptomyces, Aspergillus, and Cephalosporium.

Abstract: Attenuated pseudorabies viruses are provided which comprise DNA including a sequence essential for replication of the attenuated virus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring pseudorabies virus, and at least one foreign DNA sequence adapted for expression in a host and encoding an amino acid sequence which is antigenic in the host. These viruses are useful as vaccines for immunizing animals against pseudorabies virus disease and other pathogens.The invention also provides methods of preparing attenuated pseudorabies viruses containing at least one foreign DNA sequence and methods of immunizing animals with vaccines comprised of these viruses.

Abstract: A novel recombinant plasmid inserted with a herpes simplex virus gene, which comprises a plasmid vector containing a yeast DNA sequence and an Escherichia coli DNA sequence and carrying a promoter region and a herpes simplex virus gN gene (HSVgB) gene) recombined thereto under control of the promoter, said HSVgB gene lacking an N-terminal portion of the gene including a signal sequence-encoding region and optionally further lacking the region downstream therefrom, such as a gB gene lacking a DNA sequence encoding the N-terminal 30 amino acids, and a gB gene lacking a DNA sequence encoding the N-terminal 83 amino acids. The recombinant plasmid is useful for the production of transformed yeast, which is useful for the production of HSVgB proteins suitable for producing HSV vaccine and diagnostic reagents for herpes simplex virus infections.

Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; an origin of replication; and a fragment designated cI.sup.434 on which is included the gene for the repressor protein and its associated promoter and operator.

Abstract: A cloned single-strand DNA encoding amino acid sequence for a eukaryotic transcription factor S-11 is disclosed together with, a cloned double-strand DNA consisting of the single-strand DNA and its complementary single-strand DNA, a DNA fragment of the single- or double-strand DNA, a process for the preparation thereof, a plasmid, in which the double-strand DNA or its fragment is inserted, and a diagnosis of viral diseases and cancers.

Abstract: The present invention provides an isolated nucleic acid molecule encoding an .alpha..sub.2B -adrenergic receptor, and an isolated protein which is a human .alpha..sub.2B -adrenergic receptor.The invention also provides vectors comprising DNA molecules encoding a human .alpha..sub.2B -adrenergic receptor, and vectors adapted for expression of the .alpha..sub.2B -adrenergic receptor in bacterial, yeast, or mammalian cells.In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the .alpha..sub.2B -adrenergic receptor, a method for determining whether a ligand which is not known to be capable of binding to the .alpha..sub.2B -adrenergic receptor can bind to the .alpha..sub.2B -adrenergic receptor, a method for detecting the presence of .alpha..sub.2B -adrenergic receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the .alpha..sub.2B -adrenergic receptor.

Abstract: Attenuated pseudorabies viruses are provided which comprise DNA including a sequence essential for replication of the attenuated pseudorabies virus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring pseudorabies virus. The DNA encodes mRNAs which, in an animal infected with the attenuated pseudorabies virus, are translated into antigenic pseudorabies virus gene products which invoke in the infected animal an immunological response distinguishable from an immunological response invoked in an animal infected with a naturally-occurring pseudorabies virus. Also provided are vaccines which comprise the attenuated pseudorabies virus of the present invention and methods of immunizing animals against pesudorabies virus disease.The invention further provides a method for distinguishing an animal vaccinated with a vaccine of the present invention from an animal infected with a naturally-occuring pseudorabies virus.

Abstract: A process for controlling the glycosylation of protein in a cell wherein the cell is genetically engineered to produce one or more enzymes which provide internal control of the cell's glycosylation mechanism. A Chinese hamster ovary (CHO) cell line is genetically engineered to produce a sialyltransferase. This supplemental sialyltransferase modifies the CHO glycosylation machinery to produce glycoproteins having carbohydrate structures which more closely resemble naturally occurring human glycoproteins.

Abstract: The present invention relates to a basic protein called phospholipase A2 (PLA2), isolated from the venom of a snake of the family Elapidae, especially of a Naja snake and more particularly Naja nigricollis and/or Naja mossambica pallida, to the fragments and derivatives of the said protein, to their methods of preparation, to pharmaceutical compositions which can be used in human and/or veterinary medicine, and to diagnostic agents in which the said protein and/or its derivatives and/or its fragments are present.The said protein comprises 118 amino acids, its molecular weight is of the order of 13,300 Daltons and its isoelectric point is of the order of 8.6.The derivatives of the said protein are modified at one of the histidines by fixation of an alkyl group of the formula R--CH.sub.2 --X.Application to the detection of tumoral cells.

Abstract: A dual phage RNA polymerase promoter having a polylinker with at opposite ends, a T3 phage RNA polymerase promoter and a phage RNA polymerase promoter, like T7; the promoters are linked to the polylinker in opposite orientation. A recombinant DNA vector containing a T3 phage RNA polymerase promoter and a different phage RNA polymerase promoter; the promoters are linked to a polylinker sequence in opposite orientation. A kit including a T3 promoter and containing appropriate components for synthesizing RNA transcripts that are complementary to either strands of a cloned DNA sequence, and for other applications. Gene coding for T3 RNA polymerase, a vector containing the gene and transformed microorganisms.

Abstract: A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a rThis invention was made with government support under Grant Contract Nos. GM-27904 and GM-11557 awarded by the National Institute of Health. The government has certain rights in this invention. The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. For convenience, the reference materials are numerically referenced and grouped in the appended bibliography.

Abstract: A vector containing DNA encoding human monoamine oxidase type A is disclosed.

Abstract: IGF-I fused with a protective peptide, in which the protective peptide is a protein peptide and is used for the protection of IGF-I from degradation by protease in cells of E. coli is disclosed. Also disclosed are genes coding for the fused IGF-I's, plasmids containing the genes, and E. coli microorganisms transformed with the plasmids.

Abstract: SP6 bacteriophage RNA polymerase is produced by cultivating a new microorganism (particularly new strains of Escherichia coli) harboring a plasmid that carries SP6 bacteriophage RNA polymerase gene and recovering SP6 bacteriophage RNA polymerase from the culture broth. SP6 bacteriophage RNA polymerase gene is provided as are new microorganisms harboring a plasmid that carries SP6 bacteriophage RNA polymerase gene.

Abstract: IGF-I fused with a protective peptide, in which the protective peptide is a protein peptide and is used for the protection of IGF-I from degradation by protease in cells of E. coli is disclosed. Also disclosed are genes coding for the fused IGF-I's, plasmids containing the genes, and E. coli microorganisms transformed with the plasmids.

Abstract: This invention relates generally to recombinant DNA techniques and to the expression of mammalian polypeptides in genetically engineered eukaryotic cells. Specifically, the invention relates to preferred plasmid constructs and methods that increase levels of expression of a cloned gene product. These preferred plasmids have selectable and nonselected gene cassettes adjacent to each other and oriented in the opposite direction for transcription. Such an orientation enhances overall levels of expression for the nonselected gene. Further, this invention relates to gene products expressed at these very high levels by the herein described method, and to the eukaryotic cells derived thereby.

Abstract: A cloned single-strand DNA comprising nucleotide sequence which encodes an antibacterial polypeptide precursor, a cloned double-strand DNA consisting of the single-strand DNA and its complementary single-strand DNA, a DNA fragment of the single- or double-strand DNA, a process for the preparation thereof, and a plasmid, in which the double-strand DNA or its fragment is inserted are disclosed.